An overview of the medical management of nonmelanoma skin cancer.
Importantly, NMSCs are increasing in prevalence, and full recognition of these diseases as life-threatening entities is paramount. Overall, data supporting adjuvant or systemic therapy in NMSCs are limited, but there are enough reports in the literature to suggest some benefit with systemic agents. Where available, we recommend patients investigate clinical trial options, including phase I studies. Newer targeted therapies and activation of the immune system may provide for a dramatic step forward in the management of these diseases; however, formal clinical trials are necessary to establish these new treatments as a standard of care.
Lauren
L
Metterle
Jeffrey S
JS
Russell
Nishit S
NS
Patel
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents